title: Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
abstract: THE PARADIGM FOR THE TREATMENT OF MONOCLONAL GAMMOPATIES HAS DRAMATICALLY CHANGED: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within the last seven years. Based on the understanding of the complex interaction of the MM cells with the bone marrow microenvironment and the signaling pathways that are dysregulated in this process, a number of novel therapeutic agents are now available. Specifically, three novel agents with a specific-targeted anti-MM activity, have been FDA-approved for the treatment of this disease, namely Bortezomib, thalidomide, and lenalidomide which are now all playing a key role in the treatment of MM. The success of targeted therapy in MM has since led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenström's macroglobulinemia and primary amyloidosis, both in the preclinical settings and as part of clinical trials.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;
authors.forename: Aldo M
authors.initials: AM
authors.lastname: Roccaro
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
authors.forename: Simona
authors.initials: S
authors.lastname: Blotta
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
authors.forename: Michele
authors.initials: M
authors.lastname: Malagola
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
authors.forename: Paul G
authors.initials: PG
authors.lastname: Richardson
authors.forename: Domenico
authors.initials: D
authors.lastname: Russo
references.citation: Ann Oncol. 2005 Jan;16(1):132-8
references.pmid: 15598950
references.citation: Blood. 2004 Aug 1;104(3):607-18
references.pmid: 15090448
references.citation: Leuk Lymphoma. 2004 Oct;45(10):2047-55
references.pmid: 15370249
references.citation: Semin Oncol. 2001 Dec;28(6):607-12
references.pmid: 11740818
references.citation: Blood. 2006 Nov 15;108(10):3458-64
references.pmid: 16840727
references.citation: Blood. 2007 Jan 15;109(2):492-6
references.pmid: 16960148
references.citation: Blood. 2008 Feb 1;111(3):1654-64
references.pmid: 18006697
references.citation: Haematologica. 2005 Dec;90(12):1655-8
references.pmid: 16330439
references.citation: Ann Oncol. 2007 Aug;18(8):1369-75
references.pmid: 17693650
references.citation: Cancer Res. 2005 Jul 1;65(13):5898-906
references.pmid: 15994968
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4319-23
references.pmid: 12409330
references.citation: Eur J Cancer. 2006 Jul;42(11):1612-22
references.pmid: 16750621
references.citation: Blood. 2003 Apr 15;101(8):3126-35
references.pmid: 12515720
references.citation: J Clin Oncol. 2003 Jan 1;21(1):16-9
references.pmid: 12506164
references.citation: Cancer Cell. 2005 Nov;8(5):407-19
references.pmid: 16286248
references.citation: Ann Oncol. 2004 Oct;15(10):1481-3
references.pmid: 15367407
references.citation: Blood. 2006 Nov 15;108(10):3295-301
references.pmid: 16873669
references.citation: Blood. 2007 Jun 1;109(11):4964-72
references.pmid: 17284528
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: Br J Cancer. 2002 Nov 4;87(10):1166-72
references.pmid: 12402158
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: Neurology. 2006 Mar 14;66(5):742-4
references.pmid: 16534115
references.citation: Blood. 2004 Dec 15;104(13):4188-93
references.pmid: 15319277
references.citation: Haematologica. 2006 Jul;91(7):929-34
references.pmid: 16818280
references.citation: Cancer Res. 2007 Apr 15;67(8):3777-84
references.pmid: 17440091
references.citation: Blood. 2007 Dec 15;110(13):4417-26
references.pmid: 17761832
references.citation: Semin Oncol. 2003 Apr;30(2):265-9
references.pmid: 12720150
references.citation: J Support Oncol. 2003 Sep-Oct;1(3):194-205
references.pmid: 15334875
references.citation: Curr Opin Oncol. 2006 Nov;18(6):598-608
references.pmid: 16988581
references.citation: Blood. 2006 Feb 1;107(3):1092-100
references.pmid: 16234364
references.citation: Oncogene. 2002 Aug 22;21(37):5673-83
references.pmid: 12173037
references.citation: Blood. 2005 Sep 15;106(6):1901-10
references.pmid: 15890683
references.citation: Leuk Lymphoma. 2004 Mar;45(3):591-5
references.pmid: 15160923
references.citation: Blood. 2008 Feb 15;111(4):1805-10
references.pmid: 17875806
references.citation: Blood. 2005 Dec 15;106(13):4050-3
references.pmid: 16118317
references.citation: N Engl J Med. 2006 May 11;354(19):2079-80
references.pmid: 16696148
references.citation: Haematologica. 2006 Nov;91(11):1498-505
references.pmid: 17043025
references.citation: Lancet. 2006 Mar 11;367(9513):825-31
references.pmid: 16530576
references.citation: Blood. 2006 Nov 15;108(10):3289-94
references.pmid: 16873668
references.citation: Blood. 2002 Nov 1;100(9):3063-7
references.pmid: 12384400
references.citation: Blood. 2006 May 15;107(10):4053-62
references.pmid: 16418332
references.citation: Blood. 2001 Jul 1;98(1):210-6
references.pmid: 11418482
references.citation: Blood. 2006 May 1;107(9):3442-6
references.pmid: 16410453
references.citation: Leukemia. 2005 Oct;19(10):1831-4
references.pmid: 16121217
references.citation: Semin Oncol. 2003 Apr;30(2):243-7
references.pmid: 12720145
references.citation: J Clin Oncol. 2006 Jan 20;24(3):431-6
references.pmid: 16365178
references.citation: Clin Lymphoma. 2005 Mar;5(4):282-4
references.pmid: 15794866
references.citation: Haematologica. 2007 Aug;92(8):1149-50
references.pmid: 17650451
references.citation: J Clin Oncol. 2005 Jan 20;23(3):474-81
references.pmid: 15659493
references.citation: Blood. 2008 May 1;111(9):4752-63
references.pmid: 18316628
references.citation: Mayo Clin Proc. 2000 Sep;75(9):897-901
references.pmid: 10994824
references.citation: N Engl J Med. 1999 Nov 18;341(21):1565-71
references.pmid: 10564685
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4089-99
references.pmid: 15867202
references.citation: Br J Haematol. 2004 Oct;127(2):165-72
references.pmid: 15461622
references.citation: Haematologica. 2007 Oct;92(10):1351-8
references.pmid: 18024372
references.citation: Clin Cancer Res. 2006 Nov 15;12(22):6826-35
references.pmid: 17121904
references.citation: Clin Lymphoma. 2004 Dec;5(3):205-7
references.pmid: 15636699
references.citation: Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73
references.pmid: 16925483
references.citation: Cancer Res. 2002 Sep 1;62(17):5027-34
references.pmid: 12208757
references.citation: Haematologica. 2007 Oct;92(10):1302-7
references.pmid: 18024367
references.citation: Blood. 2002 Jun 15;99(12):4525-30
references.pmid: 12036884
references.citation: Blood. 2006 Oct 1;108(7):2165-72
references.pmid: 16772605
references.citation: Blood. 2007 Feb 15;109(4):1669-77
references.pmid: 17023575
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1849-58
references.pmid: 18347188
references.citation: Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):21-4
references.pmid: 15651173
references.citation: Blood. 2005 Apr 1;105(7):2949-51
references.pmid: 15572585
references.citation: Oncogene. 2004 Nov 18;23(54):8766-76
references.pmid: 15480425
references.citation: Cancer. 2004 Dec 1;101(11):2593-8
references.pmid: 15493038
references.citation: Blood. 2000 Nov 1;96(9):2943-50
references.pmid: 11049970